Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.32 |
| ▸ | ATP1A1 | P05023 | 3/20 | 0.31 |
| ▸ | ATP1B1 | P05026 | 3/20 | 0.31 |
| ▸ | ATP1A3 | P13637 | 3/20 | 0.31 |
| ▸ | ATP1B2 | P14415 | 3/20 | 0.31 |
| ▸ | ATP1A2 | P50993 | 3/20 | 0.31 |
| ▸ | ATP1B3 | P54709 | 3/20 | 0.31 |
| ▸ | FXYD2 | P54710 | 3/20 | 0.31 |
| ▸ | ATP1A4 | Q13733 | 3/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25908867 | 0.85 | ITK (0.31) | — | |
| SCHEMBL23324960 | 0.83 | HRH3 (0.34) | HCAR3HRH3 | |
| SCHEMBL23324958 | 0.73 | HCAR3 (0.32) | HCAR3 | |
| SCHEMBL24127267 | 0.70 | ALDH1A1 (0.40) | HRH3ADORA3 | |
| SCHEMBL25884614 | 0.67 | HCAR3 (0.33) | HCAR3 | |
| SCHEMBL25884637 | 0.66 | HCAR3 (0.65) | HCAR3 | |
| SCHEMBL23323560 | 0.66 | P4HTM (0.38) | HCAR3 | |
| SCHEMBL29222864 | 0.65 | KAT2B (0.36) | HCAR3ATP1A1ATP1B1ATP1A3ATP1B2 | |
| SCHEMBL25911214 | 0.64 | CSNK2A2 (0.39) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL24896264 | 0.63 | SYK (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230234929-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230234929-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-11566007-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20210130303-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566007-B2 | Ras inhibitors | KRAS, NRAS, HRAS | HCAR3 4500/4885ATP1A1 3647/4885ATP1B1 3207/4885 |
| US-20230234929-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | HCAR3 4500/4885ATP1A1 3647/4885ATP1B1 3207/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | HCAR3 4223/4885ATP1A1 3258/4885ATP1B1 2774/4885 |
| US-20210130303-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | HCAR3 4500/4885ATP1A1 3647/4885ATP1B1 3207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.